Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02612558 · ClinicalTrials.gov registry record · Phase 2
A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA)
A Phase 2 study of Warm Antibody Autoimmune Hemolytic Anemia, sponsored by Rigel Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
- 20
- Study locations
NCT02612558: Completed Phase 2 study of Warm Antibody Autoimmune Hemolytic Anemia, sponsored by Rigel Pharmaceuticals.
NCT02612558 is a Phase 2 study of Warm Antibody Autoimmune Hemolytic Anemia that has completed, run by Rigel Pharmaceuticals. The registered enrollment target is 26 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02612558, a Phase 2 study of Warm Antibody Autoimmune Hemolytic Anemia, has completed, sponsored by Rigel Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate whether fostamatinib is safe and effective in the treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA).
Primary Outcome
Hemoglobin level of \> 10 g/dL and 2 g/dL higher than the baseline hemoglobin
Conditions Studied
Interventions
- DRUG Fostamatinib 150 mg bid
Study Locations (20)
California
- UC San Diego Moores Cancer Center - La Jolla
- Loma Linda University Cancer Center - Loma Linda
- LAC/USC Health Center - Los Angeles
- University of California at San Francisco - San Francisco
- The Oncology Institute of Hope and Innovation - Whittier
Arizona
- Banner MD Anderson Cancer Center - Gilbert
- Arizona Oncology Associates, PC - Tucson
Maryland
- Johns Hopkins University School Of Medicine - Baltimore
- Rcca Md Llc - Bethesda
New York
- Roswell Park Cancer Institute - Buffalo
- Montefiore Medical Center - The Bronx
North Carolina
- Brody School of Medicine at East Carolina University - Greenville
- W.G. "Bill" Hefner VA Medical Center - Salisbury
District of Columbia
- MedStar Georgetown University Hospital - Washington D.C.
Florida
- Mid-Florida Hematology & Oncology Centers, P.A. - Orange City
Kentucky
- Montgomery Cancer Center - Mount Sterling
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2016-07 |
| Est. Completion | 2019-12 |
| Phase | Phase 2 |
What the finished NCT02612558 record still lists
NCT02612558 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Warm Antibody Autoimmune Hemolytic Anemia appearing as the primary indexed condition, and to 1 intervention - of which Fostamatinib 150 mg bid is the first listed.
NCT02612558 names 20 study sites across 12 states, led by California, Arizona, Maryland.
Frequently Asked Questions
What is clinical trial NCT02612558 about?
NCT02612558 is a clinical study titled "A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA)". The purpose of this study is to evaluate whether fostamatinib is safe and effective in the treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA).
What is the current status of trial NCT02612558?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2016-07. Estimated completion is 2019-12.
What conditions does trial NCT02612558 study?
This clinical trial studies the following conditions: Warm Antibody Autoimmune Hemolytic Anemia.
What interventions are being tested in trial NCT02612558?
The interventions under investigation include: Fostamatinib 150 mg bid (DRUG).
Who is sponsoring clinical trial NCT02612558?
This trial is sponsored by Rigel Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02612558 being conducted?
This trial has 20 study locations across Arizona, California, District of Columbia, Florida, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Warm Antibody Autoimmune Hemolytic Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02612558's enrollment target sits among peer trials
26 1708th of 2000 higher than 282 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia